Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Next Previous
Trial Profile

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone metastases; Breast cancer; Cancer; Cancer metastases; Multiple myeloma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Amgen

Most Recent Events

  • 19 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 29 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 11 Aug 2009 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top